Further studies investigated the frequency and phenotype of circulating immune cells and the concentration of soluble molecules in blood from anti-PD-1-treated tumor patients to identify potential biomarkers for the prediction of clinical responses. The gene discussed is PDCD1; the disease is neoplasm.